Compare Abeona Therapeutics Inc (ABEO) vs Humana Inc (HUM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Humana Inc — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Humana Inc trades at $400.08 (market cap $47.38B). The key difference: Humana Inc is far larger — about 126.9× Abeona Therapeutics Inc's market cap, and Humana Inc pays a 0.9% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | HUM | |
|---|---|---|
Market Cap | $373.32M | $47.38B |
Sector | Health | Health |
52-Week High | $7.23 | $409.42 |
52-Week Low | $4.17 | $163.67 |
Enterprise Value | $228.22M | $56.42B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Humana (HUM) trades at $394.62, down 0.54% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. Revenue growth is strong, reaching $129.66B in 2025, though net income margin has compressed to 0.82%. Recent news highlights expansion through Medicaid contracts and divestitures, alongside legal scrutiny over healthcare costs. The stock shows resilience with consistent earnings beats but faces profitability pressures.
Outlook is mixed: bullish technicals and revenue growth support upside, but margin erosion and legal risks pose challenges. Analysts are cautious with a consensus hold rating and price target of $315, below the current price. Investors should weigh solid fundamentals against regulatory and competitive headwinds for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
